These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 17472398)
1. Proniosomal powder of captopril: formulation and evaluation. Gupta A; Prajapati SK; Singh M; Balamurugan M Mol Pharm; 2007; 4(4):596-9. PubMed ID: 17472398 [TBL] [Abstract][Full Text] [Related]
2. Proniosomes as a drug carrier for transdermal delivery of ketorolac. Alsarra IA; Bosela AA; Ahmed SM; Mahrous GM Eur J Pharm Biopharm; 2005 Apr; 59(3):485-90. PubMed ID: 15760729 [TBL] [Abstract][Full Text] [Related]
3. Proniosomes as drug carriers. Sankar V; Ruckmani K; Durga S; Jailani S Pak J Pharm Sci; 2010 Jan; 23(1):103-7. PubMed ID: 20067875 [TBL] [Abstract][Full Text] [Related]
4. Biodegradable microparticulate system of captopril. Dandagi PM; Mastiholimath VS; Patil MB; Gupta MK Int J Pharm; 2006 Jan; 307(1):83-8. PubMed ID: 16310990 [TBL] [Abstract][Full Text] [Related]
5. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design. Guenette E; Barrett A; Kraus D; Brody R; Harding L; Magee G Int J Pharm; 2009 Oct; 380(1-2):80-8. PubMed ID: 19596428 [TBL] [Abstract][Full Text] [Related]
6. Controlled release application of multilamellar vesicles: a novel drug delivery approach. Agnihotri SA; Soppimath KS; Betageri GV Drug Deliv; 2010 Feb; 17(2):92-101. PubMed ID: 20067375 [TBL] [Abstract][Full Text] [Related]
7. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)--effects of formulation parameters on physicochemical stability. Teeranachaideekul V; Müller RH; Junyaprasert VB Int J Pharm; 2007 Aug; 340(1-2):198-206. PubMed ID: 17482778 [TBL] [Abstract][Full Text] [Related]
8. Vesicular powder as carrier for doxycycline hydrochloride and metronidazole combination therapy. Gad HA; Kamel AO; Sammour OA; El Dessouky HF Pharm Dev Technol; 2014 Sep; 19(6):755-68. PubMed ID: 23981239 [TBL] [Abstract][Full Text] [Related]
9. Proniosomal transdermal therapeutic system of losartan potassium: development and pharmacokinetic evaluation. Thakur R; Anwer MK; Shams MS; Ali A; Khar RK; Shakeel F; Taha EI J Drug Target; 2009 Jul; 17(6):442-9. PubMed ID: 19527115 [TBL] [Abstract][Full Text] [Related]
10. In situ niosome forming maltodextrin proniosomes of candesartan cilexetil: In vitro and in vivo evaluations. Yuksel N; Bayindir ZS; Aksakal E; Ozcelikay AT Int J Biol Macromol; 2016 Jan; 82():453-63. PubMed ID: 26455402 [TBL] [Abstract][Full Text] [Related]
11. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Mokhtar M; Sammour OA; Hammad MA; Megrab NA Int J Pharm; 2008 Sep; 361(1-2):104-11. PubMed ID: 18577437 [TBL] [Abstract][Full Text] [Related]
12. Solid lipid microparticles for the stability enhancement of the polar drug N6-cyclopentyladenosine. Dalpiaz A; Mezzena M; Scatturin A; Scalia S Int J Pharm; 2008 May; 355(1-2):81-6. PubMed ID: 18178347 [TBL] [Abstract][Full Text] [Related]
13. Technology overview and drug delivery application of proniosome. Ahmad MZ; Mohammed AA; Mokhtar Ibrahim M Pharm Dev Technol; 2017 May; 22(3):302-311. PubMed ID: 26794727 [TBL] [Abstract][Full Text] [Related]
14. Novel sugar esters proniosomes for transdermal delivery of vinpocetine: preclinical and clinical studies. El-Laithy HM; Shoukry O; Mahran LG Eur J Pharm Biopharm; 2011 Jan; 77(1):43-55. PubMed ID: 21056658 [TBL] [Abstract][Full Text] [Related]
15. Polysaccharide coated niosomes for oral drug delivery: formulation and in vitro stability studies. Sihorkar V; Vyas SP Pharmazie; 2000 Feb; 55(2):107-13. PubMed ID: 10723768 [TBL] [Abstract][Full Text] [Related]